title: [New management of phosphocalcic abnormalities in dialysis patient].
abstract: Disorders of the phosphocalcic metabolism are frequent in dialysis patients. Such disorders are difficult to treat and have negative impact on bone health, but also on cardiovascular mortality. Hyperphosphoremia is a strong predictor of cardiovascular mortality. New phosphate binders are now available in Belgium. A new molecule acting on the calcium receptor of the parathyroid glands is able to control secondary and tertiary hyperparathyroidism in dialysis patients. These new therapies, specific for dialysis patients, will be reviewed in this article.
authors.affiliation: Service de Néphrologie-Dialyse, CHU Sart Tilman, Liège, Bilgique.
authors.forename: P
authors.initials: P
authors.lastname: Delanaye
authors.forename: L
authors.initials: L
authors.lastname: Van Overmeire
authors.forename: B E
authors.initials: BE
authors.lastname: Dusbois
authors.forename: J M
authors.initials: JM
authors.lastname: Krzesinski
mesh_terms: D002128:Calcium Metabolism Disorders / Q000188:drug therapy*; D002614:Chelating Agents / Q000627:therapeutic use; D000069449:Cinacalcet; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy*; D009281:Naphthalenes / Q000627:therapeutic use; D010760:Phosphorus Metabolism Disorders / Q000188:drug therapy*; D006435:Renal Dialysis
chemical_list: D002614:Chelating Agents; D009281:Naphthalenes; D000069449:Cinacalcet